NO20002741D0 - Vaksine-blandinger omfattende kitosan, for mukosal administrasjon - Google Patents

Vaksine-blandinger omfattende kitosan, for mukosal administrasjon

Info

Publication number
NO20002741D0
NO20002741D0 NO20002741A NO20002741A NO20002741D0 NO 20002741 D0 NO20002741 D0 NO 20002741D0 NO 20002741 A NO20002741 A NO 20002741A NO 20002741 A NO20002741 A NO 20002741A NO 20002741 D0 NO20002741 D0 NO 20002741D0
Authority
NO
Norway
Prior art keywords
chitosan
mucosal administration
vaccine compositions
deacetylated
vaccine
Prior art date
Application number
NO20002741A
Other languages
English (en)
Other versions
NO20002741L (no
Inventor
Jill C Makin
Andrew D Bacon
Original Assignee
Medeva Europ Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Europ Ltd filed Critical Medeva Europ Ltd
Publication of NO20002741L publication Critical patent/NO20002741L/no
Publication of NO20002741D0 publication Critical patent/NO20002741D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20002741A 1997-11-28 2000-05-26 Vaksine-blandinger omfattende kitosan, for mukosal administrasjon NO20002741D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9725084.9A GB9725084D0 (en) 1997-11-28 1997-11-28 Vaccine compositions
PCT/GB1998/003534 WO1999027960A1 (en) 1997-11-28 1998-11-27 Vaccine compositions for mucosal administration comprising chitosan

Publications (2)

Publication Number Publication Date
NO20002741L NO20002741L (no) 2000-05-26
NO20002741D0 true NO20002741D0 (no) 2000-05-26

Family

ID=10822720

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002741A NO20002741D0 (no) 1997-11-28 2000-05-26 Vaksine-blandinger omfattende kitosan, for mukosal administrasjon

Country Status (11)

Country Link
US (1) US6534065B1 (no)
EP (1) EP1051190B1 (no)
JP (1) JP2001524532A (no)
AT (1) ATE250937T1 (no)
AU (1) AU745934B2 (no)
CA (1) CA2310718A1 (no)
DE (1) DE69818707D1 (no)
GB (1) GB9725084D0 (no)
NO (1) NO20002741D0 (no)
NZ (1) NZ504504A (no)
WO (1) WO1999027960A1 (no)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CN1253220C (zh) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂
EP1458362A4 (en) * 2001-11-19 2006-01-18 Becton Dickinson Co PHARMACEUTICAL COMPOSITIONS IN PARTICLE FORM
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
JP4697706B2 (ja) 2002-10-11 2011-06-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2191844B1 (en) 2003-01-30 2014-03-05 Novartis AG Injectable vaccines against multiple meningococcal serogroups
EP1594536B1 (en) * 2003-01-30 2009-03-25 Novartis Vaccines and Diagnostics, Inc. Adjuvanted influenza vaccine
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2004092360A2 (en) 2003-04-10 2004-10-28 Chiron Corporation The severe acute respiratory syndrome coronavirus
AU2004235744A1 (en) * 2003-05-01 2004-11-18 Archimedes Development Limited Nasal administration of the LH-RH analog leuprolide
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
CN103405761A (zh) 2003-10-02 2013-11-27 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CA2548210A1 (en) * 2003-12-05 2005-08-18 Becton, Dickinson And Company Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
EP2272531A3 (en) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration of meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US20050281886A1 (en) * 2004-05-06 2005-12-22 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
JP4896021B2 (ja) 2004-05-21 2012-03-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
CA2890962A1 (en) 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Decreasing potential iatrogenic risks associated with influenza vaccines
JPWO2006030730A1 (ja) * 2004-09-15 2008-05-15 大塚製薬株式会社 経粘膜用組成物、及び経粘膜吸収の向上方法
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CA2586690A1 (en) 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics, Inc. Influenza vaccination
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
LT2351772T (lt) 2005-02-18 2016-10-10 Glaxosmithkline Biologicals Sa Baltymai ir nukleorūgštys iš su meningitu/sepsiu susijusių escherichia coli
US20070059319A1 (en) * 2005-09-15 2007-03-15 Caliper Life Sciences, Inc. Methods of screening for immuno-adjuvants and vaccines comprising anti-microtubule immuno-adjuvants
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
DK2368572T3 (da) 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
JP2009527572A (ja) 2006-02-24 2009-07-30 ノバルティス アーゲー 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
EP2019686B1 (en) 2006-03-31 2012-07-11 Novartis AG Combined mucosal and parenteral immunization against hiv
PL2054431T3 (pl) 2006-06-09 2012-07-31 Novartis Ag Konformery adhezyn bakteryjnych
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US20080182819A1 (en) * 2007-01-29 2008-07-31 Act Iii Licensing, Llc Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
JP5297009B2 (ja) * 2007-07-24 2013-09-25 大日精化工業株式会社 免疫アジュバント水溶液
JP5259997B2 (ja) * 2007-07-24 2013-08-07 大日精化工業株式会社 免疫アジュバント分散液
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
DK2535428T3 (en) 2007-10-01 2015-11-23 Longhorn Vaccines & Diagnostics Llc Biological prøvesamlings- and transport system, and methods of using
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081274A2 (en) 2007-12-21 2009-07-02 Novartis Ag Mutant forms of streptolysin o
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
JP2009209086A (ja) * 2008-03-04 2009-09-17 Masami Moriyama 粘膜投与型ワクチン
EP2889042A3 (en) 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
CN103897045A (zh) 2009-01-12 2014-07-02 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
BRPI1013780B8 (pt) 2009-04-14 2022-10-04 Novartis Ag Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
EP2442826B1 (en) 2009-06-15 2015-07-08 National University of Singapore Influenza vaccine, composition, and methods of use
KR101342641B1 (ko) 2009-06-25 2013-12-20 주식회사 바이오리더스 폴리감마글루탐산-키토산 나노입자를 함유하는 면역보강제 조성물
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2767392C (en) 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
EP3988115A3 (en) 2009-07-15 2022-08-17 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
CN104650241A (zh) 2009-08-27 2015-05-27 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
JP2011057605A (ja) * 2009-09-09 2011-03-24 Masami Moriyama 粘膜投与型ワクチン
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
JP2013506651A (ja) 2009-09-30 2013-02-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ．ａｕｒｅｕｓ５型および８型莢膜多糖の結合体
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2519265B1 (en) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
US8765148B2 (en) * 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011127316A1 (en) 2010-04-07 2011-10-13 Novartis Ag Method for generating a parvovirus b19 virus-like particle
EP2558069A1 (en) 2010-04-13 2013-02-20 Novartis AG Benzonapthyridine compositions and uses thereof
RU2465006C2 (ru) * 2010-04-14 2012-10-27 Учреждение Российской академии медицинских наук научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова РАМН (НИИВС им. И.И. Мечникова РАМН) Способ повышения иммуногенности холодоадаптированной живой гриппозной вакцины
JP2013532008A (ja) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド 対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
EP2591097A1 (en) 2010-07-06 2013-05-15 Novartis AG Norovirus derived immunogenic compositions and methods
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
CA2812135A1 (en) 2010-09-07 2012-03-15 Novartis Ag Generic assays for detection of mammalian reovirus
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
PL2667892T3 (pl) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa Schemat szczepień przeciwko rsv
LT2707385T (lt) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Iš anksto sulieti rsv f antigenai
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
EP3508219A1 (en) 2011-07-06 2019-07-10 GlaxoSmithKline Biologicals S.A. Self-replicating rna prime - protein boost vaccines
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
US10030052B2 (en) 2011-07-25 2018-07-24 Glaxosmithkline Biologicals Sa Parvovirus Vp1 unique region polypeptides and compositions thereof
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
WO2013038385A2 (en) 2011-09-14 2013-03-21 Novartis Ag Escherichia coli vaccine combination
CN104080479B (zh) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
CA3207612A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
CN104321335A (zh) 2012-02-24 2015-01-28 诺华股份有限公司 菌毛蛋白质和组合物
CN104321078A (zh) 2012-04-26 2015-01-28 诺华股份有限公司 抗原和抗原组合
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
SG11201407440WA (en) 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
EP2895191B1 (en) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
JP2015532276A (ja) 2012-10-02 2015-11-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 非直鎖状糖コンジュゲート
CA2896552A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
EP2911676B1 (en) 2012-10-29 2020-05-20 The Board of Trustees of the University of Arkansas Novel mucosal adjuvants and delivery systems
PL2925355T3 (pl) 2012-11-30 2018-06-29 Glaxosmithkline Biologicals S.A. Antygeny pseudomonas i połączenia antygenów
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
WO2022234483A1 (en) 2021-05-04 2022-11-10 King Abdullah University Of Science And Technology Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
WO2023079529A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Re-focusing protein booster immunization compositions and methods of use thereof
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1261264A (en) 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
WO1996009805A2 (en) 1994-09-23 1996-04-04 Zonagen, Inc. Chitosan induced immunopotentiation
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9522351D0 (en) 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions

Also Published As

Publication number Publication date
JP2001524532A (ja) 2001-12-04
NO20002741L (no) 2000-05-26
EP1051190A1 (en) 2000-11-15
ATE250937T1 (de) 2003-10-15
DE69818707D1 (de) 2003-11-06
GB9725084D0 (en) 1998-01-28
AU1569199A (en) 1999-06-16
CA2310718A1 (en) 1999-06-10
AU745934B2 (en) 2002-04-11
WO1999027960A1 (en) 1999-06-10
EP1051190B1 (en) 2003-10-01
US6534065B1 (en) 2003-03-18
NZ504504A (en) 2002-05-31

Similar Documents

Publication Publication Date Title
NO20002741L (no) Vaksine-blandinger omfattende kitosan, for mukosal administrasjon
NO982497L (no) Vaksine-sammensetninger for inntak gjennom nesen
WO2002009637A3 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
NO981963L (no) Influensavaksine-blandinger
BR9814483A (pt) "vacina"
ES2118834T3 (es) Sistema mejorado de penetracion en la piel para la administracion topica mejorada de farmacos.
BR0010209A (pt) Composições para o tratamento de desordens do esÈfago
ATE322287T1 (de) Solubisierung von kapseln polysacchariden
EP0882450A3 (en) Cholesterol-lowering composition comprising coenzyme Q
BR0014939A (pt) Oligossacarìdeos, processo de preparação de oligossacarìdeos, composições farmacêuticas, e, utilização de oligossacarìdeos
PT789590E (pt) Imunopotenciacao induzida por quitosano
FI972054A (fi) Immunogeenisiä koostumuksia
HUP0301506A3 (en) Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome
SE9403905D0 (sv) New formulations
DK1154792T3 (da) Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans
BR0212259A (pt) Formulação de liberação controlada de claritromicina ou tinidazol
ATE188114T1 (de) Milde, wässrige, tensidische zubereitungen für kosmetische zwecke und reinigungsmittel
CA2255867A1 (en) Chitosan induced immunopotentiation
FR2708855B1 (fr) Compositions pharmaceutiques immunoadjuvantes ou immunostimulantes.
KR920021163A (ko) 비-자극성 백신 조성물
AU4166599A (en) Glucopyranose derivatives and preventives and/or remedies for hiv infection containing the same as the active ingredient
BR1100802A (pt) Formulação de vacina contra vìrus respiratório sincicial
JO2370B1 (en) Pharmaceutical formulations for the treatment of painful, inflamed and ulcerated conditions of wet epithelial surfaces such as mucositis, stomatitis and Behçet syndrome
CA2386534A1 (en) Crystal form ii of clarithromycin and uses thereof